These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6178592)

  • 41. Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants.
    Ljunggren HG; Sturmhöfel K; Wolpert E; Hämmerling GJ; Kärre K
    J Immunol; 1990 Jul; 145(1):380-6. PubMed ID: 2113557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stimulation of natural killer cell activity and inhibition of proliferation of various leukemic cells by purified human leukocyte interferon subtypes.
    Lee SH; Kelley S; Chiu H; Stebbing N
    Cancer Res; 1982 Apr; 42(4):1312-6. PubMed ID: 6174222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The nature of enhanced natural killer lymphocyte cytotoxicity during anesthesia and surgery in patients with benign disease and cancer.
    Griffith CD; Rees RC; Platts A; Jermy A; Peel J; Rogers K
    Ann Surg; 1984 Dec; 200(6):753-8. PubMed ID: 6210065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural cytotoxicity of human blood lymphocytes and monocytes and their cytotoxic factors: effect of interferon on target cell susceptibility.
    Uchida A; Vánky F; Klein E
    J Natl Cancer Inst; 1985 Nov; 75(5):849-57. PubMed ID: 2414505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of interferons on the inhibition of human natural killers by primary monolayer cell cultures.
    Heiskala M
    Immunology; 1987 Feb; 60(2):167-72. PubMed ID: 2434416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen.
    Roselli M; Guadagni F; Buonomo O; Belardi A; Vittorini V; Mariani-Costantini R; Greiner JW; Casciani CU; Schlom J
    J Clin Oncol; 1996 Jul; 14(7):2031-42. PubMed ID: 8683233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HLA-E/human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity.
    Weiss EH; Lilienfeld BG; Müller S; Müller E; Herbach N; Kessler B; Wanke R; Schwinzer R; Seebach JD; Wolf E; Brem G
    Transplantation; 2009 Jan; 87(1):35-43. PubMed ID: 19136889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytokines in the control of beta-2 microglobulin release. II. In vivo studies with recombinant interferons and antigens.
    Nachbaur K; Troppmair J; Kotlan B; König P; Aulitzky W; Bieling P; Huber C
    Immunobiology; 1988 Apr; 177(1):66-75. PubMed ID: 2454879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of general anesthesia and surgery on basal and interferon stimulated natural killer cell activity of humans.
    Kutza J; Gratz I; Afshar M; Murasko DM
    Anesth Analg; 1997 Oct; 85(4):918-23. PubMed ID: 9322480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low doses of interferon alpha result in more effective clinical natural killer cell activation.
    Edwards BS; Merritt JA; Fuhlbrigge RC; Borden EC
    J Clin Invest; 1985 Jun; 75(6):1908-13. PubMed ID: 4008643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients.
    Hartrich L; Weinstock-Guttman B; Hall D; Badgett D; Baier M; Patrick K; Feichter J; Hong J; Ramanathan M
    J Neuroimmunol; 2003 Jun; 139(1-2):84-92. PubMed ID: 12799025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulatory function of cell surface molecules CD2-, LFA- and beta 2-microglobulin in natural killer cell activity.
    Petrányi GG; Pócsik E; Kotlán B; Görög G; Benczur M
    Mol Immunol; 1986 Nov; 23(11):1275-9. PubMed ID: 2434840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human leukocyte interferon therapy for advanced ovarian carcinoma.
    Einhorn N; Cantell K; Einhorn S; Strander H
    Am J Clin Oncol; 1982 Apr; 5(2):167-72. PubMed ID: 6178284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interferon and spontaneous cytotoxicity in man. II. Studies in patients receiving exogenous leukocyte interferon.
    Einhorn S; Blomgren H; Strander H
    Acta Med Scand; 1978; 204(6):477-83. PubMed ID: 282781
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.
    Brunda MJ; Tarnowski D; Davatelis V
    Int J Cancer; 1986 May; 37(5):787-93. PubMed ID: 2422129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro modulation of human natural killer cell activity by interferon: generation of adherent suppressor cells.
    Uchida A; Yanagawa E; Kokoschka EM; Micksche M; Koren HS
    Br J Cancer; 1984 Oct; 50(4):483-92. PubMed ID: 6237664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Natural killer cell activity during treatment with fibroblast interferon.
    Pape GR; Hadam MR; Eisenburg J; Riethmüller G
    Immunobiology; 1981 Jun; 158(5):450-3. PubMed ID: 6167511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
    Brooks CG; Holscher M; Urdal D
    J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interferon and beta 2-microglobulin in patients with common variable immunodeficiency or selective IgA deficiency.
    Strannegård O; Björkander J; Hellstrand K; Pacsa A; Hermodsson S; Hanson LA
    Int Arch Allergy Appl Immunol; 1987; 84(3):217-22. PubMed ID: 2443457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.